GlassScriptPhysician profile
Fletcher Dane Munksgard
NPI 1992243331
$3,608.98
in general payments reported to CMS, 2019-2025
22 companies · $2,298 in 2025
The $2,298 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $237 · 2023: $89.71 · 2024: $775 · 2025: $2,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,162.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $602.00 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $422.61 | 2024-2025 | Fanapt, Ponvory |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $342.22 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $308.92 | 2024-2025 | Auvelity, Symbravo |
| Lundbeck LLC | $300.25 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $265.38 | 2023-2024 | Rexulti, Nuedexta |
| Lilly USA, LLC | $132.79 | 2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.97 | 2022 | |
| Pfizer INC. | $124.70 | 2025 | |
| Shield Therapeutics INC | $123.74 | 2024 | |
| Amneal Pharmaceuticals LLC | $119.18 | 2024-2025 | Crexont, Brekiya, Rytary |
| Corcept Therapeutics | $116.39 | 2025 | Korlym |
| Medtronic, INC. | $116.33 | 2021 | |
| Novo Nordisk INC | $112.04 | 2022 | |
| Ucb, INC. | $108.37 | 2025 | Nayzilam |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $57.65 | 2025 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $49.45 | 2025 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $48.22 | 2021 | |
| Genentech USA, INC. | $44.43 | 2021 | |
| Janssen Pharmaceuticals, INC | $35.21 | 2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $33.03 | 2025 | Trintellix |
| Biogen, INC. | $21.10 | 2025 | Spinraza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fletcher Munksgard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.